. As such, PepT1 is a potential drug design target for improving intestinal absorption and the systemic availability of poorly absorbed drug molecules [4, 24, 25] . In addition to increasing oral drug absorption, an essential step is the conversion of prodrug to its active therapeutic moiety. Recent advances in biochemistry and biology concerning the structural and functional characteristics of enzymes have provided abundant information to benefit prodrug design. More sophisticated strategies have been developed involving the covalent binding of special promoieties to relevant parent drugs. These prodrugs can then be activated by one or more enzymes presystemically, systemically or at the site of action [12, 26, 27] .
BPHL, also called human valacyclovirase, an is an α-amino acid ester hydrolase that was initially cloned from a human breast carcinoma cDNA library and found to be highly expressed in human liver and kidney [28] . BPHL protein consists of 274 amino acids containing the Gly-X-Ser-X-Gly motif, which is characteristic of serine hydrolases involved in the degradation of aromatic compounds by cleavage of carbon-carbon bonds [29] . In 2008, a study on the crystal structure and biochemical analysis of recombinant BPHL identified the key determinants for substrate recognition [30] . Specifically, these authors reported that the protein had a unique active site defined by a flexible and mostly hydrophobic acyl pocket, a localized negative electrostatic potential, and a large open leaving group-accommodating groove. Most importantly, BPHL protein also had a pivotal acidic residue, Asp-123, located after the nucleophile Ser-122, whose side chain was directed into the substrate binding pocket, thereby, playing a critical role in the substrate discriminating ability of serine hydrolases [30] . Moreover, the recombinant BPHL enzyme (originally from Caco2 cells) was shown to effectively hydrolyze many amino acid ester nucleoside prodrugs, converting compounds such as valacyclovir to acyclovir [18] and valganciclovir to ganciclovir [31] . Physiologically, BPHL was reported as a likely candidate for protecting against homocysteine thiolactone toxicity [32] .
Despite the fact that BPHL is a major enzyme for the activation of valine ester prodrugs, the in vivo impact of BPHL on prodrug stability, permeability and activation has yet to be investigated. It is also uncertain as to whether valacyclovir (and similar prodrugs) are hydrolyzed exclusively by BPHL or if other enzymes contribute to the in vivo hydrolysis (activation) of valacyclovir to acyclovir. With this in mind, the objectives of this study were to evaluate the in situ intestinal permeability and stability of valacyclovir in wildtype and Bphl knockout mice, and to determine the in vivo oral absorption and intravenous disposition of valacyclovir and acyclovir in the two mouse genotypes. This is the first time that a phenotypic, biochemical, molecular and functional assessment of BPHL ablation has been reported under both in situ and in vivo study conditions.
Materials and methods

Chemicals
Anti-mouse BPHL antiserum was generated by Lampire Biological Laboratories, Inc (Pipersville, PA USA) using the C-terminal 20 amino acid residues (HNLHLRFADEFNRLVEDFLQ, amino acids 272-291) of the protein. Valacyclovir and acyclovir were purchased from SigmaAldrich (St. Louis, MO USA). Valacyclovir-D4 and acyclovir-D4 internal standards were purchased from Toronto Research Chemicals (Toronto, Ontario Canada). Other chemicals and reagents were from standard sources.
Animals
Bphl knockout mice on a pure C57BL/6N background were generously provided by the Institut Clinique de la Souris (Illkirch Cedex, France). Animals were bred and housed in a temperature-controlled environment with 12-hour light and dark cycles. They received a standard diet and water ad libitum, as provided by the Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI. Gender-matched mice (8-10 weeks) were used in accordance with the Guide for Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health. All relevant mouse strains were validated by genotyping. 
5′-GCTGGAAGGCTGCAGTTCTG-3′ 5′-GTGCTTGTCCTGAGAAGCCTTT-3′ Cyp3a11 (EC1.14.99.38) 5′-AACTGCAGGATGAGATCGATGAG-3′ 5′-TTCATTAAGCACCATATCCAGGTATT-3′ Cyp3a16 (EC1.14.99.-) 5′-CTGCAGGAGGAGATCGATGAG-3′ 5′-CCATCGCCATCACGGTATC-3′ Cyp3a41 (EC1.14.-.-) 5′-CTGACAGACAAGCAGGGATGAA-3′ 5′-GTAGAGGAGCACCAGGATGATTG-3′ Cyp3a44 (EC1.14. 
1629 ± 197 (9) 1562 ± 344 (6) Bilirubin (mg/dL) 0.12 ± 0.01 (9) 0.10 ± 0.00 (7) BUN (mg/dL) 42 ± 5 (9) 31 ± 2 (8) ALP (U/L) 86 ± 11 (9) 105 ± 5 (8) Data are expressed as mean ± SE (number of mice). TRIG, triglycerides; CHOL, Cholesterol; AST, aspartate aminotransferase; ALP, alkaline phosphatase; CPK, creatine phosphokinase; BUN, blood urea nitrogen; ALT, alanine aminotransferase. * p ≤ 0.05, as compared to wildtype mice, using an unpaired t-test.
Initial phenotypic analysis
Wildtype and Bphl knockout mice were evaluated for viability, fertility, serum clinical chemistry and histology, as described previously [23] .
Quantitative real-time PCR (qRT-PCR) and immunoblot analysis
Gene transcripts of Bphl, PepT1, PepT2, PhT1, PhT2, Ces1, Ces2, Cyp3a11, Cyp3a16, Cyp3a41 and Cyp3a44 were evaluated in the small intestine, colon, kidney, spleen and liver of wildtype and Bphl knockout mice using the 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA), as described previously [21] . The primers are listed in Table 1 . Briefly, all reactions were performed in triplicate, where each reaction included 30 ng of cDNA that was reverse-transcribed using the Omniscript RT kit (Qiagen, Valencia, CA) and 16-mer random primers from RNA isolated using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA). The qRT-PCR thermal conditions were one cycle at 50°C for 2 min, one cycle at 95°C for 10 min, and forty cycles at 95°C for 15 s followed by 60°C for 1 min. Relative levels of the target gene transcripts in mice were calculated using the ΔCT method, where the ratio of target gene to Gapdh was equal to 2 −ΔCT , ΔCT = CT(gene) -CT (Gapdh). The mouse Gapdh gene was set as an internal control of cDNA quality and quantity. Protein levels of BPHL were determined in the liver, jejunum, spleen and kidney of wildtype and Bphl knockout mice by immunoblot analysis, as described previously [21, 33, 34] . In brief, after processing the tissues, membrane proteins were denatured at 40°C for 45 min, resolved by 7.5% SDS-PAGE, transferred to a PVDF membrane (Millipore, Billerica, MA), and then blotted for one hour with rabbit anti-mouse BPHL antisera (1:5000). The membrane was washed three times with TBST and then incubated with the secondary antibody, goat anti-rabbit IgG-HRP (1:3000) (Bio-Rad, Hercules, CA). For β-actin, the membrane was blotted with a mouse monoclonal antibody (1:1000) (Santa Cruz Biotechnology, Santa Cruz, CA), followed by the secondary antibody, goat anti-mouse IgG-HRP (1:1000) (Santa Cruz Biotechnology). The membrane was then washed five times with TBST, the UCL substrate (Millipore) added, and the x-ray film exposed and developed.
In situ single-pass intestinal perfusion studies
Prodrug design can be used to increase the permeability and stability of the parent drug [35] . The effects of Bphl gene deletion on valacyclovir permeability and stability were evaluated using in situ single-pass jejunal perfusion studies, as described previously with wildtype mice as the control group [20, 21, 23] . In brief, following an overnight fast, wildtype and Bphl knockout mice were anesthetized with sodium pentobarbital (40-60 mg/kg ip) and an 8-cm jejunal segment was isolated. The segment was then rinsed with 0.9% isotonic saline solution and a glass cannula (0.2 mm OD) was inserted at each end of the intestinal segment. Perfusion buffer (135 mM NaCl, 5 mM KCl and 10 mM MES/Tris, pH 6.5) containing 50 μM valacyclovir was perfused through the jejunal segment at a flow rate of 0.1 mL/min and the outlet perfusate was collected every 10 min for 90 min. Water flux during the perfusion was corrected by mass balance using a gravimetric method.
Hydrolysis studies were also performed in which, following jejunal perfusions of 1.0 mM valacyclovir, plasma samples were collected from the portal vein at 5 and 30 min after initiating the perfusion.
Ultra performance liquid chromatography with photodiode array detector assay conditions for in situ perfusion studies
Following centrifugation of the 100-μL perfusate samples, a 25-µL aliquot was injected into the ultra performance liquid chromatography (UPLC) system, as previously described with minor modification [36] . Specifically, the method employed a UPLC Acquity H-Class System (Waters Corp, Milford, MA) coupled to a Photodiode Array Detector set at 254 nm. A 100-cm Acquity HSS T3 column (1.8 μm) was maintained at 40°C with gradient elution at a flow rate of 0.5 mL/min. The mobile phase started with 100% water (0.1% TFA), and increased linearly to 10% acetonitrile and 90% water (0.1% TFA) over 5 min. This level was maintained for 2 min, then reverted back to 100% water (0.1% TFA) at 7 min, which was maintained until the end of the run (12 min). The lower limits of quantitation for acyclovir and valacyclovir in perfusate buffer were 50 and 10 nM, respectively.
Oral and intravenous pharmacokinetic studies
The effects of Bphl gene deletion on the oral absorption and disposition of valacyclovir were evaluated, as described previously for valacyclovir in wildtype mice [17] . For oral studies, 25 nmol/g of valacyclovir (in 0.2 mL of water per 20 g body weight) was administered by oral gavage. For intravenous bolus studies, 25 nmol/g of valacyclovir (in 0.1 mL of saline per 20 g body weight) was administered by tail vein injection. Blood samples (∼20 μL aliquots), after both dosing routes, were obtained by tail biopsy at 2, 5, 15, 30, 60, 90, 120 and 180 min post-injection, with an additional sample taken at 45 min for the oral studies. The blood samples were then mixed with 1 μL EDTA-K3 and centrifuged at 3000g for 5 min at 4°C. Following centrifugation, the plasma was harvested and a 10-μL aliquot was mixed with 40 μL of acetonitrile containing 200 nM of the internal standards VACV-d4 and ACV-d4. Samples were then centrifuged at 17,000g for 10 min at 4°C to precipitate the proteins, the supernatant transferred carefully into a new tube, and frozen at −80°C for subsequent analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
LC-MS/MS assay conditions for in vivo pharmacokinetic studies
Plasma supernatant (10 μL aliquot), obtained from the in vivo pharmacokinetic studies (see above), was analyzed by LC-MS/MS, as previously described [37] . In brief, the LC-MS/MS analysis consisted of a Shimadzu HPLC system (Shimadzu, Tokyo, Japan) coupled to an API 4000 triple quadrupole/linear ion trap (QTRAP) mass spectrometer (AB Sciex, Foster City, CA, USA). Analytes were separated on a Waters Atlantis T3 C18 column (5 μm, 150 × 2.1 mm, Dublin, Ireland). The mobile phase consisted of water containing 2 mM ammonium acetate and 0.2% formic acid (v/v) (Phase A) and acetonitrile containing 0.2% formic acid (v/v) (Phase B), which was delivered at a flow rate of 0.2 mL/min. Gradient elution was applied for compound separation and the program was timed as follows: Phase B was started at 2% for 2 min, then increased linearly to 4% over the next 2 min, further increased to 50% over the next 2 min, and then returned to 2% at 6.5 min, which was maintained until the end of run (9 min). The mass spectrometer was operated in positive ion mode using electrospray ionization. The following transitions were monitored in a multiple reaction monitoring mode: VACV, 325.2 > 152.1; ACV, 226.2 > 152.1; VACV-d4, 329.2 > 152.1; ACV-d4, 230.2 > 152.1. The lower limit of quantification was 2 nM for both valacyclovir and acyclovir.
Data analysis
Data were reported as mean ± SE, unless otherwise noted. Statistical differences between two groups were determined by an unpaired t-test using GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA). A value of p ≤ 0.05 was considered statistically significant. Pharmacokinetic analyses were carried out by noncompartmental analysis (NCA) using Phoenix WinNonlin 8.0 (Certara, St. Louis, MO USA).
Results
Initial phenotypic analysis
Bphl knockout mice appeared normal with no obvious behavioral abnormalities as compared to wildtype mice. They also had normal fertility, litter size, gender distribution, viability, and body weight. As shown in Table 2 , no significant differences were observed in serum clinical chemistry between wildtype and Bphl knockout mice, although a statistical difference was noted for sodium (i.e., 147 vs 144 mM, respectively). Histological evaluation, as judged by hematoxylin and eosin staining, demonstrated normal morphology in the small and large intestines, liver, kidney and spleen of wildtype and Bphl knockout mice (Fig. 1) .
Confirmation of BPHL ablation
Even though knockout mice were identified by genotyping, select tissues were further tested by qRT-PCR for Bphl gene expression and by immunoblotting for the presence of BPHL protein. As shown in Fig. 2A , Bphl transcripts were barely detectable in the duodenum, jejunum, ileum, colon, liver, kidney and spleen of Bphl knockout mice. In wildtype mice, Bphl mRNA expression was greatest in the kidney and liver, moderate in the colon and ileum, and low in the small intestine and spleen. This result was confirmed in Fig. 2B , where abundant expression of BPHL protein was observed in the kidney and liver of wildtype mice, but faint expression of protein in the jejunum and spleen. In contrast, no BPHL protein expression was observed in the counterpart tissues of Bphl knockout mice.
Gene expression of select transporters and enzymes in tissues from wildtype and Bphl knockout mice
It is important to know whether Bphl gene ablation resulted in a compensatory response for relevant transporters and/or enzymes of mice. The four mammalian proton-coupled oligopeptide transporters were examined first in several tissues of wildtype and Bphl knockout mice. The intestinal PepT1 transporter was of particular interest because of its strategic value as a target for improving drug (and prodrug) oral absorption. As shown in Fig. 3A , no significant differences were observed between the two genotypes in the gene expression of PepT1 in tissues, with the exception of colon in which PepT1 mRNA was increased. In regard to PepT2, no differences in gene expression were noted between wildtype and Bphl knockout mice in any of the tissues tested (Fig. 3B) . In contrast, PhT1 gene expression was increased in the duodenum, ileum, colon, kidney and spleen of Bphl knockout mice (Fig. 3C) . Finally, PhT2 gene expression was increased only in the ileum during Bphl ablation (Fig. 3D) .
Enzymes that might impact the hydrolysis of valacyclovir were examined next. As shown in Fig. 3E and 3F, no differences were observed between wildtype and Bphl knockout mice in the gene expression of Ces1 or Ces2, respectively. Although Cyp3a11 transcripts were increased in the liver during Bphl ablation (Fig. 3G ), as were Cyp3a16 transcripts in the duodenum and liver (Fig. 3H ), no differences in Cyp3a41 (Fig. 3I) and Cyp3a44 (Fig. 3J ) gene expression were discerned in any of the tissues tested between wildtype and Bphl knockout mice. Nonetheless, significant increases in Abhd14a gene expression were observed in the duodenum, kidney and spleen of Bphl knockout mice (Fig. 3K) . Likewise, during Bphl ablation, Abhd14b transcripts were significantly increased in the duodenum, ileum, colon, liver, kidney and spleen of these mice (Fig. 3L) .
Intestinal permeability and stability of valacyclovir during in situ perfusion of prodrug in wildtype and Bphl knockout mice
Single-pass jejunal perfusion studies were performed in order to evaluate the effect of Bphl gene ablation on the intestinal permeability, stability, and presystemic metabolism of valacyclovir. As shown in Fig. 4A , there was no significant difference in the effective permeability of valacyclovir in the jejunum of wildtype and Bphl knockout mice (i.e., 0.54 ± 0.10 and 0.53 ± 0.05 × 10 −4 cm/s, respectively). Moreover, valacyclovir was stable during the jejunal perfusion, as assessed by the very low appearance of acyclovir in outlet perfusate of both genotypes during the experiment, that is about 5% through 80 min and 5-10% at 90 min (Fig. 4B) . Presystemic metabolism was determined by sampling the portal vein after 5 and 30 min of jejunal perfusion of valacyclovir. As shown in Fig. 4C , after 5 min of perfusion, prodrug hydrolysis was significantly greater in wildtype mice as compared to Bphl knockout mice (i.e., 8.0 ± 1.0 vs. 23.3 ± 4.4% valacyclovir remaining intact, respectively). However, after 30 min of perfusion, there was no significant difference between genotypes in the proportion of valacyclovir found intact in portal vein blood (6.8 ± 2.3% in wildtype vs. 11.7 ± 6.7% in Bphl knockout mice).
Oral and intravenous pharmacokinetic studies of valacyclovir in wildtype and Bphl knockout mice
The effect of Bhpl ablation on valacyclovir absorption, disposition and conversion to acyclovir was evaluated in vivo after both oral and intravenous administrations. The pharmacokinetics of valacyclovir (and acyclovir) were considered first after intravenous dosing of prodrug since disposition and conversion could be evaluated in the absence of absorption. As shown in Fig. 5A , similar (but not superimposable) plasma concentration -time profiles were observed between wildtype and Bphl knockout mice for prodrug and active parent drug. On average, the C max and AUC 0-180 were about 30-40% greater for both drug species, whereas the T max for acyclovir was about 2.5-fold greater in Bphl knockout mice (Table 3 ). The changes in valacyclovir C max and AUC 0-180 , though most were not statistically significant, reflect the reduced conversion of valacyclovir to acyclovir in the absence of BPHL. The log-linear terminal half-life (T ½ ) showed only a modest difference between genotypes (i.e., 10% larger for prodrug and 20% smaller for active parent drug in Bphl knockout mice).
After oral dosing of valacyclovir, the plasma concentration -time profiles of acyclovir were quite similar between the two genotypes (Fig. 5B) . Accordingly, the C max of acyclovir was about 20% greater but the AUC 0-180 only 4% greater in Bphl knockout mice (Table 3) . Small (20%) reductions were also observed for the T max and T ½ values of acyclovir during Bphl ablation. On the other hand, larger differences were noted between genotypes for valacyclovir in which the C max and AUC 0-180 were about 50 and 70% greater, respectively, in Bphl knockout mice as compared to wildtype animals. Although no change was found in the T max of valacyclovir, a small 25% reduction was observed in the T ½ of prodrug during Bphl ablation. Interestingly, the ratio of AUC 0-180 for prodrug to active parent drug (i.e., VACV/ACV) was 70% greater after oral dosing in Bphl knockout mice. In contrast, the AUC ratio differed by only 8% between genotypes after intravenous dosing.
Collectively, these findings demonstrate that, in the absence of BPHL, other enzymes are available to convert valacyclovir to acyclovir [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] in vivo and that the conversion is more efficient after oral than intravenous administration of prodrug.
Discussion
Biphenyl hydrolase-like protein (BPHL) is a novel human serine hydrolase that was originally cloned from a breast carcinoma cDNA library [28] and, because of its ability to catalyze the hydrolytic activation of valacyclovir (to acyclovir), referred to as valacyclovirase (VACVase). VACVase, initially purified from rat liver, was reported to be a basic protein that associated intracellularly with mitochondria [38] . This enzyme was further characterized by studying its hydrolysis kinetics for six amino acid esters of acyclovir, including that of valacyclovir. A human valacyclovirase was later identified from the human colon carcinoma cell line, Caco-2 [18] , after which the human gene was cloned and a crystal structure characterized [30] . Although several studies investigated the hydrolytic activation for a broad range of amino acid ester nucleoside prodrugs by BPHL [18, 31, 39] , no study has yet evaluated the in vivo exclusivity of this process. Indeed, a number of esterases/proteases may mediate the hydrolysis of valacyclovir and similar prodrugs.
In this study, the in situ intestinal permeability and stability of valacyclovir were evaluated during jejunal perfusions, and the in vivo absorption and disposition of valacyclovir (and acyclovir) evaluated during oral and intravenous bolus dosing of prodrug in wildtype and Bphl knockout mice. The use of transgenic mice, in which the Bphl gene was ablated, offers a unique opportunity to test the relative importance of BPHL in hydrolyzing valacyclovir, as compared to other possible enzymes. Major findings of this study revealed, for the first time, that: 1) no obvious phenotype was observed for Bphl knockout mice; 2) enzymatic upregulation of Cyp3a11, Cyp3a16, Abhd14a and Abhd14b was observed in some tissues of Bphl knockout mice; 3) Bphl ablation had no effect on the jejunal permeability of valacyclovir in mice; 4) valacyclovir was stable during intestinal perfusions and, following absorption, was found mostly as acyclovir (> 75%) in portal vein blood; 5) valacyclovir was rapidly and efficiently hydrolyzed to acyclovir in vivo in the absence of BPHL; and 6) hydrolysis was more extensive after the oral vs. intravenous route of administration (for both genotypes), as judged by the 10-to 20-fold higher AUC 0-180 values of acyclovir to valacyclovir after oral dosing as compared to the only 2-to 3-fold higher AUC 0-180 values of acyclovir to valacyclovir after intravenous dosing. Taken as a whole, BPHL is not obligatory for the in vivo conversion of valacyclovir prodrug to its active parent drug acyclovir.
Assuming that BPHL was solely responsible for valacyclovir to acyclovir hydrolysis, one would have expected substantial differences between wildtype and Bphl knockout mice in the systemic exposure of valacyclovir and acyclovir following oral and intravenous administrations of prodrug. Although some differences in AUC 0-180 were noted, none of the changes achieved a level of statistical significance. For example, after oral administration of prodrug, the AUC 0-180 of valacyclovir was increased 70%, the AUC 0-180 of acyclovir was essentially unchanged, and the VACV/ACV ratio was increased 70% in Bphl knockout mice. In contrast, after intravenous administration of prodrug, the AUC 0-180 of valacyclovir was increased 30%, the AUC 0-180 of acyclovir was increased 40%, and the VACV/ACV ratio was essentially unchanged in Bphl knockout mice. Thus, during BPHL ablation, the hydrolysis of valacyclovir to acyclovir was less extensive following oral dosing, suggesting that presystemic metabolism of valacyclovir was more important than systemic metabolism of prodrug. This finding is corroborated by our in situ jejunal perfusion results in mice showing that, as early as 5 min, < 10% of valacyclovir remains intact in portal vein blood, and by studies in humans showing that valacyclovir is nearly completely converted to acyclovir by first-pass intestinal and/or hepatic metabolism [40] .
Ces1 and Ces2 are mouse carboxylesterases that are expressed in the liver (CES1 predominates in human) and small intestine (contains CES2 alone in human), and hydrolyze ester prodrugs, including the antiviral substrates valacyclovir and oseltamivir [41] . Cyp3a11, Cyp3a16, Cyp3a41 and Cyp3a44 are mouse orthologs of the human CPY3A4/5 genes that are highly expressed in both small intestine and liver, and account for the metabolism in over 50% of clinically used drugs [42] . Abhd14a and Abhd14b are mouse orthologs of the human hydrolases (ABHD14A/B) that are expressed about equally in most human tissues, with lowest expressions in brain, testis and placenta [12] . They are believed to have some role in transcriptional initiation and have been shown to hydrolyze the model substrate p-nitrophenyl butyrate. Although the present study design did not allow us to identify which additional enzymes were involved in the hydrolysis of valacyclovir during BPHL ablation, some compensatory (upregulatory) mechanisms were noted in Bphl knockout mice. For instance, gene expression was significantly increased for Cyp3a16 in the duodenum and liver, and for Abhd14a in the duodenum, ileum and kidney of mice lacking the Bphl gene. More prevalent changes were observed for Abhd14b in which gene expression was significantly increased in the duodenum, ileum, colon, liver, kidney and spleen of Bphl knockout mice. Although speculative, the increased exposure of ACV in Bphl knockout mice, after intravenous administration of VACV, might be the result of significant upregulation of Abhd14a/b in the liver, kidney and spleen ( Fig. 3K and  3L) .
In regard to the proton-coupled oligopeptide transporters, PepT1 was upregulated in the colon of Bphl knockout mice. However, this change is unlikely to have a significant impact on the in vivo pharmacokinetic results because valacyclovir is almost entirely absorbed in the small intestine [43] . Significant changes in the gene expression of PhT1 and PhT2 are also unlikely to impact the absorption of valacyclovir since these transporters are not expressed at the apical membrane of small intestinal epithelia but are, instead, located intracellularly [44] .
In conclusion, the in situ intestinal permeability and stability of valacyclovir, and in vivo absorption and disposition of valacyclovir (and acyclovir) were evaluated after oral and intravenous administrations in wildtype and Bphl knockout mice. Whereas the jejunal permeability of valacyclovir was unchanged between the two genotypes, rapid and extensive hydrolysis of prodrug was still evident in mice even during Bphl gene deletion. Thus, BPHL is not obligatory for the in vivo conversion of valacyclovir to acyclovir either presystemically or systemically. The relevance of the upregulation of mouse Abhd14a and/or Abhd14b hydrolases in small intestinal segments, liver, kidney and spleen is currently unknown but deserves further attention.
